Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations
Condition(s):Advanced Solid Tumor; CNS Tumor; Recurrent WHO Grade II GliomaLast Updated:February 23, 2023Withdrawn